Baseline factors associated with response to ruxolitinib

Francesca Palandri; Giuseppe Alberto Palumbo; Massimiliano Bonifacio; Mario Tiribelli; Giulia Benevolo; Bruno Martino; Elisabetta Abruzzese; Mariella D'Adda; Nicola Polverelli; Micaela Bergamaschi; Alessia Tieghi; Francesco Cavazzini; Adalberto Ibatici; Monica Crugnola; Costanza Bosi; Roberto Latagliata; Ambra Di Veroli; Luigi Scaffidi; Federico de Marchi; Elisa Cerqui; Barbara Anaclerico; Giovanna De Matteis; Marco Spinsanti; Elena Sabattini; Lucia Catani; Franco Aversa; Francesco Di Raimondo; Umberto Vitolo; Roberto Massimo Lemoli; Renato Fanin; Francesco Merli; Domenico Russo; Antonio Cuneo; Maria Letizia Bacchi Reggiani; Michele Cavo; Nicola Vianelli; Massimo Breccia

Baseline factors associated with response to ruxolitinib

Francesca Palandri, Giuseppe Alberto Palumbo, Massimiliano Bonifacio, Mario Tiribelli, Giulia Benevolo, Bruno Martino, Elisabetta Abruzzese, Mariella D'Adda, Nicola Polverelli, Micaela Bergamaschi, Alessia Tieghi, Francesco Cavazzini, Adalberto Ibatici, Monica Crugnola, Costanza Bosi, Roberto Latagliata, Ambra Di Veroli, Luigi Scaffidi, Federico de Marchi, Elisa CerquiBarbara Anaclerico, Giovanna De Matteis, Marco Spinsanti, Elena Sabattini, Lucia Catani, Franco Aversa, Francesco Di Raimondo, Umberto Vitolo, Roberto Massimo Lemoli, Renato Fanin, Francesco Merli, Domenico Russo, Antonio Cuneo, Maria Letizia Bacchi Reggiani, Michele Cavo, Nicola Vianelli, Massimo Breccia

Research output: Contribution to journal › Article › peer-review

Abstract

In patients with Myelofibrosis (MF) treated with ruxolitinib (RUX), the response is unpredictable at therapy start. We retrospectively evaluated the impact of clinical/laboratory factors on responses in 408 patients treated with RUX according to prescribing obligations in 18 Italian Hematology Centers. At 6 months, 114 out of 327 (34.9%) evaluable patients achieved a spleen response. By multivariable Cox proportional hazard regression model, pre-treatment factors negatively correlating with spleen response were: high/intermediate-2 IPSS risk (p=0.024), large splenomegaly (p=0.017), transfusion dependency (p=0.022), platelet count 2 years (p=0.048). Also, patients treated with higher (≥10 mg BID) average RUX doses in the first 12 weeks achieved higher response rates (p=0.019). After adjustment for IPSS risk, patients in spleen response at 6 months showed only a trend for better survival compared to non-responders. At 6 months, symptoms response was achieved by 85.5% of 344 evaluable patients; only a higher (>20) Total Symptom Score significantly correlated with lower probability of response (p

Original language	English
Pages (from-to)	79073-79086
Number of pages	14
Journal	Oncotarget
Volume	8
Issue number	45
Publication status	Published - Oct 3 2017

Keywords

Journal Article

Cite this

Palandri, F., Palumbo, G. A., Bonifacio, M., Tiribelli, M., Benevolo, G., Martino, B., Abruzzese, E., D'Adda, M., Polverelli, N., Bergamaschi, M., Tieghi, A., Cavazzini, F., Ibatici, A., Crugnola, M., Bosi, C., Latagliata, R., Di Veroli, A., Scaffidi, L., de Marchi, F., ... Breccia, M. (2017). Baseline factors associated with response to ruxolitinib. Oncotarget, 8(45), 79073-79086.

Palandri, F, Palumbo, GA, Bonifacio, M, Tiribelli, M, Benevolo, G, Martino, B, Abruzzese, E, D'Adda, M, Polverelli, N, Bergamaschi, M, Tieghi, A, Cavazzini, F, Ibatici, A, Crugnola, M, Bosi, C, Latagliata, R, Di Veroli, A, Scaffidi, L, de Marchi, F, Cerqui, E, Anaclerico, B, De Matteis, G, Spinsanti, M, Sabattini, E, Catani, L, Aversa, F, Di Raimondo, F, Vitolo, U, Lemoli, RM, Fanin, R, Merli, F, Russo, D, Cuneo, A, Bacchi Reggiani, ML, Cavo, M, Vianelli, N & Breccia, M 2017, 'Baseline factors associated with response to ruxolitinib', Oncotarget, vol. 8, no. 45, pp. 79073-79086.

@article{a47a3f2c4c3a4d529f3a1080129d75f7,

title = "Baseline factors associated with response to ruxolitinib",

abstract = "In patients with Myelofibrosis (MF) treated with ruxolitinib (RUX), the response is unpredictable at therapy start. We retrospectively evaluated the impact of clinical/laboratory factors on responses in 408 patients treated with RUX according to prescribing obligations in 18 Italian Hematology Centers. At 6 months, 114 out of 327 (34.9%) evaluable patients achieved a spleen response. By multivariable Cox proportional hazard regression model, pre-treatment factors negatively correlating with spleen response were: high/intermediate-2 IPSS risk (p=0.024), large splenomegaly (p=0.017), transfusion dependency (p=0.022), platelet count 2 years (p=0.048). Also, patients treated with higher (≥10 mg BID) average RUX doses in the first 12 weeks achieved higher response rates (p=0.019). After adjustment for IPSS risk, patients in spleen response at 6 months showed only a trend for better survival compared to non-responders. At 6 months, symptoms response was achieved by 85.5% of 344 evaluable patients; only a higher (>20) Total Symptom Score significantly correlated with lower probability of response (p",

keywords = "Journal Article",

author = "Francesca Palandri and Palumbo, {Giuseppe Alberto} and Massimiliano Bonifacio and Mario Tiribelli and Giulia Benevolo and Bruno Martino and Elisabetta Abruzzese and Mariella D'Adda and Nicola Polverelli and Micaela Bergamaschi and Alessia Tieghi and Francesco Cavazzini and Adalberto Ibatici and Monica Crugnola and Costanza Bosi and Roberto Latagliata and {Di Veroli}, Ambra and Luigi Scaffidi and {de Marchi}, Federico and Elisa Cerqui and Barbara Anaclerico and {De Matteis}, Giovanna and Marco Spinsanti and Elena Sabattini and Lucia Catani and Franco Aversa and {Di Raimondo}, Francesco and Umberto Vitolo and Lemoli, {Roberto Massimo} and Renato Fanin and Francesco Merli and Domenico Russo and Antonio Cuneo and {Bacchi Reggiani}, {Maria Letizia} and Michele Cavo and Nicola Vianelli and Massimo Breccia",

year = "2017",

month = oct,

day = "3",

language = "English",

volume = "8",

pages = "79073--79086",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "45",

}

TY - JOUR

T1 - Baseline factors associated with response to ruxolitinib

AU - Palandri, Francesca

AU - Palumbo, Giuseppe Alberto

AU - Bonifacio, Massimiliano

AU - Tiribelli, Mario

AU - Benevolo, Giulia

AU - Martino, Bruno

AU - Abruzzese, Elisabetta

AU - D'Adda, Mariella

AU - Polverelli, Nicola

AU - Bergamaschi, Micaela

AU - Tieghi, Alessia

AU - Cavazzini, Francesco

AU - Ibatici, Adalberto

AU - Crugnola, Monica

AU - Bosi, Costanza

AU - Latagliata, Roberto

AU - Di Veroli, Ambra

AU - Scaffidi, Luigi

AU - de Marchi, Federico

AU - Cerqui, Elisa

AU - Anaclerico, Barbara

AU - De Matteis, Giovanna

AU - Spinsanti, Marco

AU - Sabattini, Elena

AU - Catani, Lucia

AU - Aversa, Franco

AU - Di Raimondo, Francesco

AU - Vitolo, Umberto

AU - Lemoli, Roberto Massimo

AU - Fanin, Renato

AU - Merli, Francesco

AU - Russo, Domenico

AU - Cuneo, Antonio

AU - Bacchi Reggiani, Maria Letizia

AU - Cavo, Michele

AU - Vianelli, Nicola

AU - Breccia, Massimo

PY - 2017/10/3

Y1 - 2017/10/3

N2 - In patients with Myelofibrosis (MF) treated with ruxolitinib (RUX), the response is unpredictable at therapy start. We retrospectively evaluated the impact of clinical/laboratory factors on responses in 408 patients treated with RUX according to prescribing obligations in 18 Italian Hematology Centers. At 6 months, 114 out of 327 (34.9%) evaluable patients achieved a spleen response. By multivariable Cox proportional hazard regression model, pre-treatment factors negatively correlating with spleen response were: high/intermediate-2 IPSS risk (p=0.024), large splenomegaly (p=0.017), transfusion dependency (p=0.022), platelet count 2 years (p=0.048). Also, patients treated with higher (≥10 mg BID) average RUX doses in the first 12 weeks achieved higher response rates (p=0.019). After adjustment for IPSS risk, patients in spleen response at 6 months showed only a trend for better survival compared to non-responders. At 6 months, symptoms response was achieved by 85.5% of 344 evaluable patients; only a higher (>20) Total Symptom Score significantly correlated with lower probability of response (p

AB - In patients with Myelofibrosis (MF) treated with ruxolitinib (RUX), the response is unpredictable at therapy start. We retrospectively evaluated the impact of clinical/laboratory factors on responses in 408 patients treated with RUX according to prescribing obligations in 18 Italian Hematology Centers. At 6 months, 114 out of 327 (34.9%) evaluable patients achieved a spleen response. By multivariable Cox proportional hazard regression model, pre-treatment factors negatively correlating with spleen response were: high/intermediate-2 IPSS risk (p=0.024), large splenomegaly (p=0.017), transfusion dependency (p=0.022), platelet count 2 years (p=0.048). Also, patients treated with higher (≥10 mg BID) average RUX doses in the first 12 weeks achieved higher response rates (p=0.019). After adjustment for IPSS risk, patients in spleen response at 6 months showed only a trend for better survival compared to non-responders. At 6 months, symptoms response was achieved by 85.5% of 344 evaluable patients; only a higher (>20) Total Symptom Score significantly correlated with lower probability of response (p

KW - Journal Article

M3 - Article

SN - 1949-2553

VL - 8

SP - 79073

EP - 79086

JO - Oncotarget

JF - Oncotarget

IS - 45

ER -

Baseline factors associated with response to ruxolitinib

Abstract

Keywords

Fingerprint

Cite this